Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
21.10.23 | AstraZeneca: IMFINZI (durvalumab) plus LYNPARZA (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer | 806 | Business Wire | IMFINZI reduced the risk of disease progression or death by 29% vs. chemotherapy First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP inhibition in advanced or recurrent... ► Artikel lesen | |
21.10.23 | AnHeart Therapeutics' Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial | 558 | Business Wire | Taletrectinib also shrank tumors in 57 percent of people with ROS1-positive NSCLC who had previously been treated with a ROS1 TKI in the trial Taletrectinib continues to be generally well tolerated... ► Artikel lesen | |
21.10.23 | Aviapartner Extends Footprint Through Joint Venture With South Africa | 517 | Business Wire | Aviapartner, leading Airport Ground Services group in Europe, enters a Joint Venture with Colossal to serve airlines and passengers in South Africa. With this partnership, the Belgium headquartered... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
NVIDIA | 6.011 |
EVOTEC | 3.246 |
NEL | 2.035 |
PLUG POWER | 1.706 |
TUI | 1.581 |
GAMESTOP | 1.472 |
BIONTECH | 1.358 |
BAYER | 1.049 |
JINKOSOLAR | 979 |
RHEINMETALL | 844 |
MERCEDES-BENZ | 753 |
SUPER MICRO COMPUTER | 741 |
VOLKSWAGEN | 724 |
TESLA | 709 |
CUREVAC | 664 |
AIXTRON SE | 655 |
DEUTSCHE LUFTHANSA | 647 |
SIEMENS ENERGY | 630 |
BYD | 621 |
RENK GROUP | 592 |
COMMERZBANK | 584 |
DEUTSCHE BANK | 575 |
PORSCHE AG | 561 |
MICROSOFT | 549 |
REDCARE PHARMACY | 534 |